Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The savage agent
- Respiratory syncytial virus
- Human RSV bronchiolitis
- Antibody to RSV against age
- Age incidence of bronchiolitis
- Global burden due to RSV
- Impact of paediatric RSV disease in USA
- The Sigurs study
- Wheezing and asthma after RSV infection
- RSV and recurrent wheeze in preterm infants
- RSV in the over 65s
- RSV-related deaths according to age
- Seasonal deaths due to RSV
- Respiratory syncytial virus through the ages
- Evaluation of RSV vaccine and PI vaccine in kids
- RSV disease in vaccinated infants
- Vaccine-augmented disease
- Infected vaccinees had poor antibody responses
- Immunological facts and puzzles
- Animal models of RSV disease
- RSV infection in inbred mice
- RSV infection in mice: time course of disease
- Mouse infection with A2 strain RSV
- TCLs clear virus but augment lung pathology
- Importance of age at first viral infection (1)
- Importance of age at first viral infection (2)
- Disease after sensitisation to RSV proteins
- Enhanced disease in cattle with FI-RSV (1)
- Enhanced disease in cattle with FI-RSV (2)
- FI-RSV vaccination/RSV challenge protocol
- Formalin-inactivated vaccines hypersensitivity
- BAL Tregs post-RSV are ablated by vaccine
- Immunoregulation restored by Tregs
- Excess of immune activation or defect of regulation
- Uses and limits of the mouse model
- Human challenge study design
- Adult volunteer RSV infection protocol
- Infection rates and colds
- Symptoms and RSV load
- Some important questions
- Serum neutralising antibody
- Nasal IgA
- Predicted protective effect of nasal RSV-IgA
- In infected volunteers, antibody is transient
- Antiviral B cell and T cell immunity in the lungs
- RSV vaccine snapshot
- RSV with codon-deoptimised NS1 & NS2 genes
- Structure of pre-fusion F
- RSV F trimer nanoparticle vaccine
- Immunogenicity of RSV subunit vaccine
- Ad-RSV/MVA prime boost vaccine
- VLPs/BLPs
- Summary
- Interventions to interrupt RSV disease
Topics Covered
- The savage agent: respiratory syncytial virus
- The importance of age
- Immunological facts and puzzles
- Animal models of RSV disease
- Human RSV vaccine studies
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Openshaw, P. (2015, June 24). Respiratory syncytial virus vaccine development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 23, 2024, from https://doi.org/10.69645/AUVA9449.Export Citation (RIS)
Publication History
Financial Disclosures
- Peter Openshaw has been a member of scientific advisory committees and/or spoken at meetings organised by Janssen, Sanofi, Moderna, Seqirus, AstraZeneca and GSK.
Other Talks in the Series: Vaccines
Transcript
Please wait while the transcript is being prepared...
0:00
I'm Peter Openshaw.
I'm the Professor of
Experimental Medicine
at Imperial College London.
And I've been working on
Respiratory Syncytial
Virus for more years
than I care to remember,
actually, since about 1985.
And what I'm going to do today
is to summarize some of the most
important background about RSV,
talk a bit about animal models
for vaccine development, and
then the current vaccines that
are under development, and
where I think the vaccine
field is going in the future.
0:31
So first a bit about
Respiratory Syncytial Virus.
It was first named the
Chimpanzee Coryza Agent
by a group that had
been studying chimps
and found that some of the
chimp handlers had common colds
and that the chimps
had common colds, too.
It was subsequently renamed,
Respiratory Syncytial
Virus by Bob Chanock,
but I think that the name
is a very regrettable one.
I think that if instead
it had been called,
the "Savage Agent," the
whole history of RSV research
would have been changed.
I've been trying to get the name
changed to the Savage Agent,
but nobody seems to take
this very seriously.
1:10
Respiratory Syncytial Virus, quite
extraordinarily a successful virus.
It's distributed worldwide.
In temperate climates, it tends
to undergo winter epidemics.
So every winter we know
there's going to be
a big outbreak of RSV disease.
And hugely successful in that
it manages to infect about 65%
of children the first year of life.
By the third year,
it up to about 96%.
So virtually everyone gets infected,
and everyone gets reinfected, as well.
So if you take adult volunteers,
you put RSV into the nose,
you tend to again get a common cold.
So that's atypical.
Or most viruses, if you infect
once and then try and infect again,
you won't be successful.
So it's a very intriguing
virus immunologically.
It's usually a mild
disease, but because it
infects so many children,
it's actually a major cause
of hospital admissions.
So in many parts of world,
it's the commonest single cause
of hospitalization during infancy.
And, as I said, it causes about
70% of cases of bronchiolitis.
So in us, it just
causes coughs and colds,
but it's obviously
a danger to younger
children, in that we can transmit
that cough or cold to them.
There's also an association with wheezing,
which I'll talk a little bit more about later.